ARA 290

Research-centric overview

Peptide

ARA 290

Community effect votes, structured logs, and side-effect summaries.

Effect profile (overview)

Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Apr 17, 2026

Studies indexed

Human

Animal

AI analyzed

Evidence mix0% human · 50% animal · 0% cellular · 0% review

Highest phase: PreclinicalYears covered: 2023

Librarian pulse — latest actionsFull changelog ↓

Apr 20, 12:41 AMtask_runCompleted task: Refresh content for ARA 290
Apr 20, 12:41 AMRefreshedRefreshed content for ARA 290
Apr 20, 12:41 AMSummarizedAuto-summarized study: "Semantic Scholar search for ARA 290..."

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

Effects of ARA 290, a Non-hematopoietic Erythropoietin Analogue, on Glucose Tolerance, Insulin Secretion, Insulin Sensitivity and Long-term Glucose Control in Individuals With Prediabetes and/or Drug-naive Type 2 Diabetes; a Phase II Study.Clinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the effects of ARA 290 on glucose tolerance, insulin secretion, insulin sensitivity, and long-term glucose control in individuals with prediabetes and/or drug-naive type 2 diabetes. The study was a Phase II trial, but specific dosage and duration details are not reported in the abstract. No therapeutic claims are made.

Phase: PHASE2Status: UNKNOWN

A Phase II Clinical Trial on the Use of ARA 290 for the Treatment of Diabetic Macular OedemaClinical TrialClinicalTrials.govApr 16, 2026

This study investigated the effects of ARA 290 on diabetic macular edema in patients. The specific dose and duration were not reported in the abstract. The outcomes measured were not detailed in the abstract.

Phase: PHASE2Status: TERMINATED

Neuropathy and Foot Ulcer_ Specific Quality of Life Instrument (Neuro QOL) Arabic Version: Cross-cultural Adaptation, Validity, and Reliability for Patients With Type 2 DiabetesClinical TrialClinicalTrials.govApr 16, 2026

This study focuses on the cross-cultural adaptation, validity, and reliability of the Neuro QOL Arabic version for patients with Type 2 diabetes. The specific peptide ARA 290 is not mentioned in the context of treatment or dosage. The findings are relevant for assessing quality of life in this patient population.

Status: RECRUITING

A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisClinical TrialClinicalTrials.govApr 16, 2026

This study measured the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms in subjects with sarcoidosis. The study was double-blind and placebo-controlled. Specific doses and outcomes were not reported in the abstract.

Phase: PHASE2Status: COMPLETED

Semantic Scholar search for ARA 290StudySemanticScholarDec 12, 2025

Not reported in abstract.

Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.StudyPubMedDec 12, 2025

ARA290 showed a 30% reduction in brain tissue damage in a mouse model of stroke, but the clinical relevance of these findings in humans is unclear.

The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.StudyPubMedDec 12, 2025

Not reported in abstract.

Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.StudyPubMedDec 12, 2025

The study explores the anti-inflammatory effects of Clarstatin in a mouse model of uveitis, but specific results and clinical implications remain unclear.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.

Librarian Changelog

Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.

8h agotask_runlibrarian-runner

Completed task: Refresh content for ARA 290

8h agoRefreshdiscovery50%

Refreshed content for ARA 290

8h agoSummarySemanticScholar0%

Auto-summarized study: "Semantic Scholar search for ARA 290..."